drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR-T)
drug_description
Autologous T cells engineered to express a chimeric antigen receptor targeting CD19, administered as a single IV infusion after lymphodepletion to deplete CD19+ B-lineage cells and modulate humoral autoimmunity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a CD19-specific chimeric antigen receptor recognize and bind CD19 on B-lineage cells, triggering T-cell activation, proliferation, and cytotoxic killing (perforin/granzyme). This results in deep depletion of CD19+ B cells (including naive, memory, and plasmablasts), reducing autoantibody production and B cell–mediated immune activation after lymphodepletion and a single IV infusion.
drug_name
CD19-directed CAR-T cells
nct_id_drug_ref
NCT06569472